Search - tctmd.com

Displaying 181 - 200 of 943

Sort: Relevancy | Date

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

News Daily News

SAXOPHONE Bolsters Apixaban for Pediatric Heart Disease

December 05, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

What’s Going to Be Hot at AHA 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

November 07, 2023

TCTMD’s Top 10 Most Popular Stories for October 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

November 01, 2023

RADIANCE Modest Renal Denervation Effect Remains at 6 Months

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

October 31, 2023

TCT 158: The Impact of Sex And Age On Long-term Outcome After Percutaneous Coronary Interventions – A Pooled Analysis Of The Randomized Controlled SORT OUT Trials

Presentation TCT 2023

TCT 158: The Impact of Sex And Age On Long-term Outcome After Percutaneous Coronary Interventions – A Pooled Analysis Of The Randomized Controlled SORT OUT Trials

Presenter: Emil Holck

October 26, 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Cardiac Surgeons Issue ‘Call to Action’ to Improve CABG Outcomes in Women

News Conference News EACTS 2023

Cardiac Surgeons Issue ‘Call to Action’ to Improve CABG Outcomes in Women

Michael O'Riordan

October 06, 2023

MESA Data Can Lend Context to Incidental CAC Findings

News Daily News

MESA Data Can Lend Context to Incidental CAC Findings

Yael L. Maxwell

September 29, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

TCTMD’s Top 10 Most Popular Stories for August 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2023

September 04, 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

ESC Endocarditis Guidelines Get First Update in 8 Years

News Conference News ESC 2023

ESC Endocarditis Guidelines Get First Update in 8 Years

August 31, 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.